clopidogrel

Clopidogrel (SR-25990C), a P2Y12 receptor antagonist, decreases platelet aggregation.

Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y12 receptor (IC50 = 100 nM). Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite via CYP2C19 in the liver enables its anti-aggregating activity. Marketed under the name Plavix , clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascular ischemic events for patients without deficiencies in CYP2C19-related metabolism.

Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex.

Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) , a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation.

(±) Clopidogrel hydrogen sulfate (Iscover) , an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Clopidogrel Related Compound C is an isomer of Clopidogrel. Clopidogrel is a P2Y12 receptor antagonist that reduces platelet aggregation, used to prevent thrombotic events in coronary artery disease, peripheral artery disease, and cerebrovascular disease.

Clopidogrel Carboxylic Acid hydrochloride (SR 26334) is a major inactive metabolite of clopidogrel, accounting for 85% of circulating clopidogrel, and is produced by hydrolysis by esterases. CLPM is commonly used as a reference standard for metabolic analysis of clopidogrel.

2-oxo Clopidogrel((±)-SR-121683)) is a drug metabolite and thiolactone intermediate of Clopidogrel, which is catalyzed by hepatic cytochrome P450 (P450) enzymes via CYP3A oxidation, and is capable of further post hydrolysis to the active metabolite CAM.Clopidogrel is an antithrombotic pro-drug.

cis-Clopidogrel-MP derivative, also known as Clopidogrel-MP-AM, is a 3'-methoxyacetophenone derivative of Clopidogrel active metabolite. This compound is an orally-active platelet inhibitor specifically targeting the P2Y12 receptor.

Clopidogrel thiolactone (2-oxoclopidogrel) is a potent P2Y12 receptor inhibitor and a potent antiplatelet aggregation compound.Clopidogrel thiolactone is the active metabolic intermediate resulting from the first oxidative activation of Clopidogrel.

Clopidogrel carboxylic acid is a useful organic compound for research related to life sciences.

Clopidogrel carboxylic acid (Standard) is a reference standard for research and analysis in studies involving Clopidogrel carboxylic acid. Clopidogrel Related Compound A is a useful organic compound for research related to life sciences. The catalog number is T125853 and the CAS number is 144457-28-3.

Clopidogrel-related Compound B hydrochloride is a useful organic compound for research related to life sciences. The catalog number is T125846 and the CAS number is 144750-52-7.

Clopidogrel-β-D-glucuronide is a metabolite of Clopidogrel. It directly interacts with the CYP2C8 enzyme and strongly inhibits the hepatic enzyme CYP2C8.

Clopidogrel-d3 (hydrogen sulfate) is the deuterated form of Clopidogrel hydrogen sulfate. This compound is an anti-platelet agent that prevents thrombus formation by inhibiting platelet aggregation induced by ADP. Clopidogrel hydrogen sulfate effectively inhibits CYP2B6 and CYP2C19 with IC₅₀ values of 18.2 nM and 524 nM, respectively, and it is also an orally active P2Y(12) inhibitor.

cis-Clopidogrel-MP-13C-d3 Derivative is the 13C and deuterated compound of cis-Clopidogrel-MP Derivative.

Clopidogrel (Standard) is a reference standard for research and analysis in studies involving Clopidogrel. Clopidogrel (SR-25990C), a P2Y12 receptor antagonist, decreases platelet aggregation.

(E)-Mpb Derivatised Clopidogrel Am Metabolite Hydrochloride (Standard) is a reference standard of (E)-Mpb Derivatised Clopidogrel Am Metabolite Hydrochloride intended for quantitative analysis, quality control, and related biochemical research applications.

rac-Clopidogrel-d4 Carboxylic Acid is a deuterated compound of rac-Clopidogrel Carboxylic Acid. rac-Clopidogrel Carboxylic Acid has a CAS number of 113665-84-2. Clopidogrel, a P2Y12 receptor antagonist, decreases platelet aggregation.

rac-Clopidogrel-d4 Hydrogen Sulfate is a deuterated compound of rac-Clopidogrel Hydrogen Sulfate. rac-Clopidogrel Hydrogen Sulfate has a CAS number of 135046-48-9. Clopidogrel, an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Becondogrel (2-Oxoclopidogrel) is a metabolite of Clopidogrel. It irreversibly inhibits the P2Y12 receptor, thereby preventing platelet aggregation and thrombosis.

Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).

Ticagrelor metabolite M5 (T437700) is a metabolite of Ticagrelor, the first reversible oral antagonist of P2Y12 receptor. Compared to Clopidogrel, Ticagrelor has faster and more consistent inhibition on ADP-receptors. Ticagrelor is used in the treatment of acute coronary syndromes (ACS).

Atorvastatin, an orally active HMG-CoA reductase inhibitor, effectively lowers blood lipids by activating liver cytochrome p450 to accelerate metabolism. Atorvastatin inhibits the proliferation and invasion of human SV-SMC cells with IC50 values of 0.39 μM and 2.39 μM, respectively. [Atorvastatin] combined with clopidogrel may lead to increased thrombotic events in patients.